Anti-Inflammatory Drugs

Clinical Ocular Pharmacology

Volumn , Issue , 2008, Pages 221-244

  Sendrowski, David P ^a   Jaanus, Siret D ^a   Semes, Leo Paul ^b,c   Stern, Michael E ^d  

^a SOUTHERN CALIFORNIA COLLEGE OF OPTOMETRY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University Optometric Group   (United States)

^d ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349157100     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-7576-5.50017-3     Document Type: Chapter

References (58)

1. Androudi S, Letko E, Meniconi M, et al., Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. AAO Annual Meeting 2003. November 15-18, Anaheim, CA.
2. Armaly MF Genetic factors related to glaucoma. Ann N Y Acad Sci 1968, 151:861-875.
3. Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and non-steroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003, 136:593-602.
4. Beck RW, Cleary PA, Anderson MA, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581-588.
5. Becker B The genetic problem of chronic simple glaucoma. Ann Ophthalmol 1971, 3:351-354.
6. Cardillo JA, Melo LAS, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmol 2005, 112:1557-1563.
7. Ciulla TA, Walker JD, Fong DS, Criswell MH Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 2004, 15:211-220.
8. Jonas JB, Kreissig I, Degearing R Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003, 87:24-27.
9. Leibowitz HM, Kupferman A Periocular injection of corticosteroids. Arch Ophthalmol 1977, 95:311-314.
10. Leibowitz HM, Kupferman A Topically administered corticosteroids. Effects on antibiotic-related bacterial keratitis. Arch Ophthalmol 1986, 98:1287-1290.
11. Leibowitz HM, Lass JH, Kupferman A Quantitation of inflammation in the cornea. Arch Ophthalmol 1974, 92:427-430.
12. Leibowitz HM, Ryan WJ, Kupferman A Comparative anti-inflammatory efficacy of topical corticosteroids with low glaucoma-inducing potential. Arch Ophthalmol 1992, 110:118-120.
13. Leopold IH The steroid shield in ophthalmology. Trans Am Acad Ophthalmol Otolaryngol 1967, 71:273-289.
14. Leopold IH, Purnell JE, Camon EJ Local and systemic cortisone in ocular disease. Am J Ophthalmol 1951, 34:361-371.
15. MacGregor RR, Sheagren HN, Lipsett MD, WolffSM Alternate day prednisone therapy. N Engl J Med 1969, 280:1427-1431.
16. Martins JC, Wilensky JT, Asseth CF, et al. Corticosteroid-induced uveitis. Am J Ophthalmol 1974, 77:433-437.
17. Reichle ML Complications of intravitreal steroid injections. Optometry 2005, 76:450-460.
18. Rhen T, Cidlowski JA Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005, 353:1711-1723.
19. Weinreb RN, Bloom E, Baxter JD, et al. Detection of glucocorticoid receptors in cultured human trabecular cells. Invest Ophthalmol Vis Sci 1981, 21:403-407.
20. Assouline M, Renard G, Arne JL, David T, et al. A prospective randomized trial of topical soluble 0.1% indomethacin versus 0.1% diclofenac versus placebo for the control of pain following excimer laser photorefractive keratectomy. Ophthalmic Surg Lasers 1998, 29:365-374.
21. Calder LA, Balasubramanian S, Fergusson D Topical nonsteroidal anti-inflammatory drugs for corneal abrasions: meta-analysis of randomized trials. Acad Emerg Med 2005, 12:467-473.
22. Chiba T, Kashiwagi K, Chiba N, Tsukahara S Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol 2006, 90:314-317.
23. Cupples HP, Lefler WH, Pulido JS, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991, 112:514-519.
24. Donnenfeld ED, Donnenfeld A Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 2006, 46:21-40.
25. Flach AJ, Jampol LM, Weinberg D, et al. Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Am J Ophthalmol 1999, 127:148-152.
26. Hargrave SL, Jung JC, Fini ME, et al. The possible role of the vitamin E solubilizer in topical diclofenac on matrix metalloproteinase expression in corneal melting. An analysis of postoperative keratolysis. Ophthalmology 2002, 109:343-350.
27. KraffM, et al. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology 1982, 89:885-890.
28. Lane SS, Modi SS, Lehmann RP, Holland EJ Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007, 33:53-58.
29. Lindstrom R The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery. Int Ophthalmol Clin 2006, 46:7-11.
30. Lindstrom R, Kim T Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin 2006, 22:397-404.
31. Perry HD, Donnenfeld An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother 2006, 7:10-99.
32. Sivaprasad S, Bunce C, Patel N. Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No. CD004239.
33. Sivaprasad S, Bunce C, Wormald R Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol 2005, 89:1420-1422.
34. Barber LD, Pflugfelder SC, Tauber J, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005, 112:1790-1794.
35. Bielory L Ocular allergy and dry eye syndrome. Curr Opin Allergy Clin Immunol 2004, 4:421-424.
36. Cetinkaya A, Akova YA, Dursun D, Pelit A Topical cyclosporine in the management of shield ulcers. Cornea 2004, 23:194-200.
37. Cosar CB, Laibson PR, Cohen EJ, Rapuano CJ Topical cyclosporine in pediatric keratoplasty. Eye Contact Lens 2003, 29:103-107.
38. Damico FM, Kiss S, Young LH Sympathetic ophthalmic. Semin Ophthalmol 2005, 20:191-197.
39. Fox RI, Stern ME Sjögren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol 2002, 116:3-13.
40. Kawson RL Characteristics of a canine model of KCS: effective treatment of topical cyclosporine. Adv Exp Med Biol 1994, 350:583-594.
41. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome. Arch Ophthalmol 2000, 118:1489-1496.
42. Lemp MA Report of the national eye institute/industry workshop on clinical trials in dry eyes. CLAO J 1995, 21:22-232.
43. Luo L, Li D-Q, Doshi A, et al. Experimental dry eye induced expression of inflammatory cytokines (IL-1a and TNF-a), MMP-9 and activated MAPK by the corneal epithelium [Abstract]. Invest Ophthalmol Vis Sci 2003, 44. E-Abstract 1026.
44. McDermott AM, Perez V, Huang AJW, et al. Pathways of corneal and ocular surface inflammation: a perspective from the Cullen symposium. Ocul Surf 2005, 3:S-131-S-138.
45. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
46. Nagra PK, Rapuano CJ, Cohen EJ, Laibson PR Thygeson's superficial punctate keratitis: ten years' experience. Ophthalmology 2004, 111:34-37.
47. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006, 25:171-175.
48. Pflugfelder SC Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004, 137:337-342.
49. Reinhard T, Sundmacher R Topical cyclosporine A in Thygeson's superficial punctate keratitis. Graefe's Arch Clin Exp Ophthalmol 1999, 237:109-112.
50. Sall K, Stevenson OD, Munford TK, et al. Two multicenter randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology 2000, 107:31-639.
51. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998, 17:584-589.
52. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 2004, 78:409-416.
53. Stern ME, Siemasko KF, Niederkorn JY The Th1/Th2 paradigm in ocular allergy. Curr Opin Allergy Clin Immunol 2005, 5:446-450.
54. Stevenson D, Tauber J, Reis BL Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging study, randomized trial. The cyclosporine A phase 2 study group. Ophthalmology 2000, 107:967-974.
55. Stonecipher K, Perry HD, Gross RH, et al. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin 2005, 21:1057-1063.
56. Strong B, Farley W, Stern ME, Pflugfeelder SC Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 2005, 24:80-85.
57. Theofilopoulous AN, Koundouris S, Kono DH, Lawson BR The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res 2001, 3:136-141.
58. Vroman DT, Sandoval HP, Fernandez de Dastro LE, et al. Effect of hinge location on corneal sensation and dry eye after laser in situ keratomileusis for myopia. J Cataract Refract Surg 2005, 31:1881-1887.